This adverse event was triggered by retroviral integration at the LMO2 locus and further driven by the acquisition of a complex set of somatic mutations, some of which are well known to occur in T-ALL, thus recapitulating our current knowledge on disease development as experienced in other GT trials. The gene discussed is LMO2; the disease is acute lymphoblastic leukemia.